SIRNAOMICS-B Surges Over 9% Intraday, Cumulative Gains Exceed 530% This Year

Deep News09-10

SIRNAOMICS-B (02257) surged over 9% during intraday trading, with cumulative gains exceeding 530% year-to-date. As of press time, the stock was up 7.27% to HK$22.12, with trading volume reaching HK$33.02 million.

SIRNAOMICS recently announced a share placement to four investors, including Huaxi Biological Technology (Hong Kong), at a 19.84% discount, totaling 17.3524 million new shares. Huaxi Biological (688363.SH) stated that it invested approximately 138 million yuan through its wholly-owned subsidiary to subscribe to the strategic placement shares of SIRNAOMICS. Upon completion of the placement, the company will hold approximately 9.44% stake in SIRNAOMICS.

According to reports, this investment by Huaxi Biological aims to advance SIRNAOMICS' research and development and commercialization processes in medical aesthetics, aging intervention, and regenerative medicine fields. The company will allocate substantial resources particularly toward the STP705 targeted fat reduction project and other siRNA-based medical aesthetics pipeline assets, including clinical development expertise and commercialization capabilities in Greater China and globally.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1199835048?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-10 11:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1199835048","market":"sg","top_or_hot":-1,"title":"SIRNAOMICS-B Surges Over 9% Intraday, Cumulative Gains Exceed 530% This Year","media":"Deep News","content":"<p>SIRNAOMICS-B (02257) surged over 9% during intraday trading, with cumulative gains exceeding 530% year-to-date. As of press time, the stock was up 7.27% to HK$22.12, with trading volume reaching HK$33.02 million.</p>\n<p>SIRNAOMICS recently announced a share placement to four investors, including Huaxi Biological Technology (Hong Kong), at a 19.84% discount, totaling 17.3524 million new shares. Huaxi Biological (688363.SH) stated that it invested approximately 138 million yuan through its wholly-owned subsidiary to subscribe to the strategic placement shares of SIRNAOMICS. Upon completion of the placement, the company will hold approximately 9.44% stake in SIRNAOMICS.</p>\n<p>According to reports, this investment by Huaxi Biological aims to advance SIRNAOMICS' research and development and commercialization processes in medical aesthetics, aging intervention, and regenerative medicine fields. The company will allocate substantial resources particularly toward the STP705 targeted fat reduction project and other siRNA-based medical aesthetics pipeline assets, including clinical development expertise and commercialization capabilities in Greater China and globally.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SIRNAOMICS-B Surges Over 9% Intraday, Cumulative Gains Exceed 530% This Year</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSIRNAOMICS-B Surges Over 9% Intraday, Cumulative Gains Exceed 530% This Year\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time\">2025-09-10 11:11</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>SIRNAOMICS-B (02257) surged over 9% during intraday trading, with cumulative gains exceeding 530% year-to-date. As of press time, the stock was up 7.27% to HK$22.12, with trading volume reaching HK$33.02 million.</p>\n<p>SIRNAOMICS recently announced a share placement to four investors, including Huaxi Biological Technology (Hong Kong), at a 19.84% discount, totaling 17.3524 million new shares. Huaxi Biological (688363.SH) stated that it invested approximately 138 million yuan through its wholly-owned subsidiary to subscribe to the strategic placement shares of SIRNAOMICS. Upon completion of the placement, the company will hold approximately 9.44% stake in SIRNAOMICS.</p>\n<p>According to reports, this investment by Huaxi Biological aims to advance SIRNAOMICS' research and development and commercialization processes in medical aesthetics, aging intervention, and regenerative medicine fields. The company will allocate substantial resources particularly toward the STP705 targeted fat reduction project and other siRNA-based medical aesthetics pipeline assets, including clinical development expertise and commercialization capabilities in Greater China and globally.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02257","symbol_name":"圣诺医药-B","start_time":0,"source_url":"","article_id":"1199835048","we_media_id":"1039043262","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1199835048","pubTimestamp":1757473905,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Deep News","introduction":"Global Stock Market Deep Analysis","home_visible":1,"id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"SIRNAOMICS-B (02257) surged over 9% during intraday trading, with cumulative gains exceeding 530% year-to-date. As of press time, the stock was up 7.27% to HK$22.12, with trading volume reaching...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02257":"圣诺医药-B","BK1161":"生物科技"},"translate_title":"圣诺-B盘中大涨超9%今年以来累计涨幅超530%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02257":1},"content_text":"SIRNAOMICS-B (02257) surged over 9% during intraday trading, with cumulative gains exceeding 530% year-to-date. As of press time, the stock was up 7.27% to HK$22.12, with trading volume reaching HK$33.02 million.\nSIRNAOMICS recently announced a share placement to four investors, including Huaxi Biological Technology (Hong Kong), at a 19.84% discount, totaling 17.3524 million new shares. Huaxi Biological (688363.SH) stated that it invested approximately 138 million yuan through its wholly-owned subsidiary to subscribe to the strategic placement shares of SIRNAOMICS. Upon completion of the placement, the company will hold approximately 9.44% stake in SIRNAOMICS.\nAccording to reports, this investment by Huaxi Biological aims to advance SIRNAOMICS' research and development and commercialization processes in medical aesthetics, aging intervention, and regenerative medicine fields. The company will allocate substantial resources particularly toward the STP705 targeted fat reduction project and other siRNA-based medical aesthetics pipeline assets, including clinical development expertise and commercialization capabilities in Greater China and globally.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1199835048","isCrawlerRequest":true}